Unknown PHASE2 INTERVENTIONAL 2-arm NCT00960518

TACE and Adefovir Compared With Transarterial Chemoembolization (TACE) Alone for Hepatitis B Virus (HBV)-Related Unresectable Hepatocellular Carcinoma (HCC) (TACE)

Combination Therapy With TACE and Adefovir Compared With TACE Alone for HBV-related Unresectable Hepatocellular Carcinoma

Sponsor: Interventional Radiology Research Group, Shanghai Radiology Society

Conditions Hepatitis B Virus Hepatocellular Carcinoma

Interventions TACE adefovir

Updated 4 times since 2017 Last updated: Aug 14, 2009 Started: Aug 31, 2009 Primary completion: Aug 31, 2012 Completion: Aug 31, 2015

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00960518, this PHASE2 trial focuses on Hepatitis B Virus and Hepatocellular Carcinoma and remains ongoing. Sponsored by Interventional Radiology Research Group, Shanghai Radiology Society, it has been updated 4 times since 2009, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

4 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE2
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE2

Status: Unknown Status → Unknown
Jan 2021 — Jul 2024 [monthly]

Unknown Status PHASE2
Jan 2017 — Jan 2021 [monthly]

Unknown Status PHASE2

First recorded

Aug 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Interventional Radiology Research Group, Shanghai Radiology Society
Tongji University

Data source: Tongji University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Ha'er'bin, China
• Shanghai, China